Nicolas Zubrzycki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nicolas Zubrzycki has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Liang Joo Leow
St. Vincent's Private Hospital Sydney New South Wales Australia
3 shared publications Austin Chin Chwan Ng
Cardiology, Concord Hospital and The University of Sydney, Concord, New South Wales, Australia
1 shared publicationBen Freedman
Charles Perkins Centre, Heart Research Institute, University of Sydney, Sydney, New South Wales, Australia
1 shared publication- Bethany Greentree1 shared publication
Boroumand Farzaneh
The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia
1 shared publication- Bunmi Sherifat Malau-Aduli
School of Medicine and Public Health, University of Newcastle
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004232
Comparative performance of stroke risk scores in patients with atrial fibrillation with low stroke risk
Background: Australian guidelines recommend the CHA 2 DS 2 -VA (congestive heart failure, hypertension, age ≥75 years (double weight), diabetes mellitus, previous stroke (double weight), vascular disease, age 65–74 years) score to identify patients with atrial fibrillation (AF) at low stroke risk who should avoid oral anticoagulation. Treatment thresholds were derived from heterogeneous international data, and alternate scores require validation in an Australian population. We evaluated whether existing stroke scores (CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke (double weight)), CHA 2 DS 2 -VA, ATRIA (anticoagulation and risk factors in atrial fibrillation) and Modified-CHADS 2 ) accurately identify truly low-risk patients in Australia. Methods: We conducted a population-based cohort study using linked data from the New South Wales Admitted Patient Data Collection, the National Death Index and the Pharmaceutical Benefits Scheme databases. Oral anticoagulant-naïve patients with a first hospital admission for AF between July 2003 and January 2021 were included. Patients were followed for ≥12 months and classified into low-risk, intermediate-risk or high-risk categories for each score. ‘Truly low-risk’ was defined as annual ischaemic stroke incidence 2 ) to 50.9% (ATRIA). Patients assigned low-risk using each score, and intermediate-risk with the CHA 2 DS 2 -VA score, met the definition of truly low-risk. Concordance-statistics were modest, with the weakest performing score being the CHA 2 DS 2 -VA score (0.61, 95% CI 0.60 to 0.61) and the best performing model being the ATRIA score (0.66, 95% CI 0.66 to 0.67). Conclusions: The guideline-endorsed CHA 2 DS 2 -VA score showed the lowest discrimination, and patients classified as intermediate-risk using this score had stroke incidence below the treatment threshold. Strong consideration should be given to the development and validation of locally applicable risk tools.
- 17 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004232
Open AccessComparative performance of stroke risk scores in patients with atrial fibrillation with low stroke risk
Background: Australian guidelines recommend the CHA 2 DS 2 -VA (congestive heart failure, hypertension, age ≥75 years (double weight), diabetes mellitus, previous stroke (double weight), vascular disease, age 65–74 years) score to identify patients with atrial fibrillation (AF) at low stroke risk who should avoid oral anticoagulation. Treatment thresholds were derived from heterogeneous international data, and alternate scores require validation in an Australian population. We evaluated whether existing stroke scores (CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke (double weight)), CHA 2 DS 2 -VA, ATRIA (anticoagulation and risk factors in atrial fibrillation) and Modified-CHADS 2 ) accurately identify truly low-risk patients in Australia. Methods: We conducted a population-based cohort study using linked data from the New South Wales Admitted Patient Data Collection, the National Death Index and the Pharmaceutical Benefits Scheme databases. Oral anticoagulant-naïve patients with a first hospital admission for AF between July 2003 and January 2021 were included. Patients were followed for ≥12 months and classified into low-risk, intermediate-risk or high-risk categories for each score. ‘Truly low-risk’ was defined as annual ischaemic stroke incidence 2 ) to 50.9% (ATRIA). Patients assigned low-risk using each score, and intermediate-risk with the CHA 2 DS 2 -VA score, met the definition of truly low-risk. Concordance-statistics were modest, with the weakest performing score being the CHA 2 DS 2 -VA score (0.61, 95% CI 0.60 to 0.61) and the best performing model being the ATRIA score (0.66, 95% CI 0.66 to 0.67). Conclusions: The guideline-endorsed CHA 2 DS 2 -VA score showed the lowest discrimination, and patients classified as intermediate-risk using this score had stroke incidence below the treatment threshold. Strong consideration should be given to the development and validation of locally applicable risk tools.
- Open Access
- 11 February 2025
- Published by Health Education and Training Institute - HETI in Health Education in Practice: Journal of Research for Professional Learning
- Vol. 8 (1)
Preparedness for internship – a mixed-methods evaluation of the assistant in medicine program
Purpose: The transition from medical student to doctor is often daunting. With compulsory hands-on clinical exposure and pre-internship training included in Australian medical education, this study aims to explore whether the Assistant in Medicine (AiM) program contributed to students’ feelings of internship preparedness. Methodology: Participants were 2022–2023 alumni of the Joint Medical Program (JMP), run by the Universities of Newcastle and New England. All participants completed the Embedded Senior Medical Student (ESMS) program, a pre-internship program integrated into the final-year curriculum. Most participants also chose to participate in the AiM program. A mixed-method design was utilised to explore the experiences and perceived preparedness for internship. Part 1, a questionnaire, was distributed to eligible participants, focusing on common activities undertaken as a medical student and/or AiM. Identified patterns were used to guide Part 2, focus group discussions. Findings: While the survey data suggested that ESMS students and AiMs had similar exposures to tasks/procedures, focus group discussions revealed key differences in terms of level of independence of practice, type of work performed, sense of responsibility and opportunities to receive teaching. Research implications: This study contributes to the growing body of literature investigating the impact of the AiM program on medical student experience. It also highlights aspects of medical education perceived as valuable for internship preparedness. Practical implications: Further research exploring the AiM program should be utilised to help guide the design of medical school curriculums in relation to preparedness for internship. Originality/value: This study was the first of its kind to investigate the similarities and differences between student placements and the AiM program in Australia. Limitations: Given the retrospective nature of this study, there is a possibility of recall bias. There was a small study population with few participants not taking part in the AiM program.
- 11 February 2025
- Published by Health Education and Training Institute - HETI in Health Education in Practice: Journal of Research for Professional Learning
- Vol. 8 (1)
Open AccessPreparedness for internship – a mixed-methods evaluation of the assistant in medicine program
Purpose: The transition from medical student to doctor is often daunting. With compulsory hands-on clinical exposure and pre-internship training included in Australian medical education, this study aims to explore whether the Assistant in Medicine (AiM) program contributed to students’ feelings of internship preparedness. Methodology: Participants were 2022–2023 alumni of the Joint Medical Program (JMP), run by the Universities of Newcastle and New England. All participants completed the Embedded Senior Medical Student (ESMS) program, a pre-internship program integrated into the final-year curriculum. Most participants also chose to participate in the AiM program. A mixed-method design was utilised to explore the experiences and perceived preparedness for internship. Part 1, a questionnaire, was distributed to eligible participants, focusing on common activities undertaken as a medical student and/or AiM. Identified patterns were used to guide Part 2, focus group discussions. Findings: While the survey data suggested that ESMS students and AiMs had similar exposures to tasks/procedures, focus group discussions revealed key differences in terms of level of independence of practice, type of work performed, sense of responsibility and opportunities to receive teaching. Research implications: This study contributes to the growing body of literature investigating the impact of the AiM program on medical student experience. It also highlights aspects of medical education perceived as valuable for internship preparedness. Practical implications: Further research exploring the AiM program should be utilised to help guide the design of medical school curriculums in relation to preparedness for internship. Originality/value: This study was the first of its kind to investigate the similarities and differences between student placements and the AiM program in Australia. Limitations: Given the retrospective nature of this study, there is a possibility of recall bias. There was a small study population with few participants not taking part in the AiM program.
- Open Access
- 31 January 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (5) , 1554-1559
Facial psoriasis in the etiology of prolonged erythema following medium‐depth chemical peels for severe photodamage
Background: Chemical peeling is the controlled wounding of the epidermis and dermis for skin rejuvenation, involving the application of ablative agents to induce keratolysis and regeneration of damaged cell layers. Prolonged erythema is one complication of this procedure. We report the prevalence and probable etiology of prolonged facial erythema in a cohort of patients treated with medium‐depth chemical peels.Materials and Methods: A retrospective audit was conducted of all medium‐depth facial chemical peels performed at two major teaching hospitals. All patients had severe facial photodamage affecting at least 75% surface area of the face. The occurrence of prolonged erythema following this peel was then identified and analyzed.Results: Of our treatment cohort (n = 82, 51 women, 31 men) with 60 years mean (61.3 years for women, 56.7 years for men), 10 patients (12%; eight women, two men) experienced prolonged erythema beyond a month of treatment. Facial psoriasis was not apparent at the time of chemical peel but manifested as prolonged erythema beyond the expected timeframe following the procedure.Conclusion: When patients experience prolonged erythema beyond a month of treatment and fail to respond to standard treatments, clinicians should examine carefully for extra‐facial psoriasis prior to this procedure, and also consider facial psoriasis a possible cause of prolonged post‐peel erythema.
- 31 January 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (5) , 1554-1559
Open AccessFacial psoriasis in the etiology of prolonged erythema following medium‐depth chemical peels for severe photodamage
Background: Chemical peeling is the controlled wounding of the epidermis and dermis for skin rejuvenation, involving the application of ablative agents to induce keratolysis and regeneration of damaged cell layers. Prolonged erythema is one complication of this procedure. We report the prevalence and probable etiology of prolonged facial erythema in a cohort of patients treated with medium‐depth chemical peels.Materials and Methods: A retrospective audit was conducted of all medium‐depth facial chemical peels performed at two major teaching hospitals. All patients had severe facial photodamage affecting at least 75% surface area of the face. The occurrence of prolonged erythema following this peel was then identified and analyzed.Results: Of our treatment cohort (n = 82, 51 women, 31 men) with 60 years mean (61.3 years for women, 56.7 years for men), 10 patients (12%; eight women, two men) experienced prolonged erythema beyond a month of treatment. Facial psoriasis was not apparent at the time of chemical peel but manifested as prolonged erythema beyond the expected timeframe following the procedure.Conclusion: When patients experience prolonged erythema beyond a month of treatment and fail to respond to standard treatments, clinicians should examine carefully for extra‐facial psoriasis prior to this procedure, and also consider facial psoriasis a possible cause of prolonged post‐peel erythema.
- Open Access
- 13 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (2) , 710-711
An innovative technique for thread‐lifting the neck using a nonbarbed nylon suture
- 13 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (2) , 710-711
Open AccessAn innovative technique for thread‐lifting the neck using a nonbarbed nylon suture
- Open Access
- 23 August 2022
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 15, 1729-1736
Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report
Elevated levels of inflammatory mediators—including the interleukin IL-23—are implicated in the pathogenesis of pyoderma gangrenosum (PG), an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, suppurative ulcers and cribriform scarring. Here, we present the first case report of significant response of isolated ulcerative PG with tildrakizumab, a biologic agent directed against the p19 subunit of IL-23, in an elderly woman with extensive treatment-refractory PG on her left leg. Tildrakizumab (100 mg subcutaneously at weeks 0 and 4, then every 8 weeks, and eventually increased in frequency to every 6 weeks), combined with acetic acid soaks each morning and chemical debridement every evening with 3% hydrogen peroxide, resulted in progressive decrease in ulcer size and depth, re-epithelialization, and recovery of sensory perception. This report describes the dramatic clinical response of ulcerative PG on the leg with tildrakizumab.
- 23 August 2022
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 15, 1729-1736
Open AccessRecalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report
Elevated levels of inflammatory mediators—including the interleukin IL-23—are implicated in the pathogenesis of pyoderma gangrenosum (PG), an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, suppurative ulcers and cribriform scarring. Here, we present the first case report of significant response of isolated ulcerative PG with tildrakizumab, a biologic agent directed against the p19 subunit of IL-23, in an elderly woman with extensive treatment-refractory PG on her left leg. Tildrakizumab (100 mg subcutaneously at weeks 0 and 4, then every 8 weeks, and eventually increased in frequency to every 6 weeks), combined with acetic acid soaks each morning and chemical debridement every evening with 3% hydrogen peroxide, resulted in progressive decrease in ulcer size and depth, re-epithelialization, and recovery of sensory perception. This report describes the dramatic clinical response of ulcerative PG on the leg with tildrakizumab.